Should I Buy ASBP? ASBP 2026 Analysis

Should You Buy Aspire Biopharma Holdings Inc (ASBP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.460

1 Day change

10.61%

52 Week Range

632.000

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: the broader trend is bearish (SMA_200 > SMA_20 > SMA_5) and pattern-based odds point to further downside over the next day/week/month.
With no Intellectia buy signals (AI Stock Picker/SwingMax) and no near-term catalysts, the risk-reward favors avoiding/standing aside rather than buying immediately.
If already holding, this setup leans toward reducing exposure into any bounce rather than adding.

Technical Analysis

Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Trend: Bearish structure with moving averages stacked down (SMA_200 > SMA_20 > SMA_5), indicating the prevailing trend remains down.
Momentum: MACD histogram is positive (0.032) and expanding, suggesting a short-term bounce attempt, but it’s counter-trend versus the bearish MA stack.
RSI (6): ~35.1 (neutral-to-weak). It’s not clearly oversold enough to provide a strong mean-reversion “must-buy” signal.
Key levels:
- Support: S1 ~1.46 (near current pre-market 1.56), S2 ~1.215.
- Resistance: Pivot ~1.857, then R1 ~2.255.
Quant/pattern read-through: Similar-pattern projection indicates ~80% chance of -3.35% next day, -7.57% next week, -15.3% next month—bearish bias dominates despite modest MACD improvement.

Positive Catalysts

- Price is trading relatively close to S1 support (~1.46), which can sometimes produce short-lived technical bounces.
- MACD histogram is positive and expanding, hinting at improving near-term momentum.
- Gross margin reported at ~45.54% (stable), which is a constructive operational datapoint if it persists.

Neutral/Negative Catalysts

- Primary trend remains bearish (downward MA alignment), which typically overrides short-term momentum flashes.
- No news in the last week: no clear event-driven catalyst to force a re-rating or sustained breakout.
- Forward-looking pattern/quant signal set is notably negative (projected declines across 1D/1W/1M).
- Trading trends: Hedge funds and insiders are neutral—no supportive “smart money” accumulation signal.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: 1,941, 0.00% YoY (flat; no growth momentum indicated).
Net income: -1,850,493, +244.59% YoY (improvement, but still a sizeable loss).
EPS: -1.49, -46.21% YoY (worsened EPS vs prior year, contradicting the net income improvement and signaling ongoing per-share pressure).
Overall: fundamentals do not show a clear accelerating growth story yet; profitability remains negative.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target updates were provided in the data, implying no visible recent Wall Street change in stance.
Wall Street pro view (inferred from available info): limited—absence of rating/target momentum and no catalysts suggests low conviction/coverage.
Wall Street con view (inferred from available info): continued losses and weak/flat revenue trend reduce the case for aggressive near-term buying.

Analyst Rating

Wall Street analysts forecast ASBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASBP is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold